Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen
Wall Street Zen upgraded Aardvark Therapeutics (NASDAQ:AARD) from "strong sell" to "sell," while the broader analyst consensus on MarketBeat remains a "hold" with a $16.30 price target. The clinical-stage biopharmaceutical company, specializing in treatments for autoimmune and inflammatory diseases, reported a quarterly loss of …